A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

By Tarun Sai Lomte From laboratory models to small human trials, a new review explores whether popular metabolic drugs could help curb alcohol, nicotine, and drug use, while underscoring how much ...

Q. I’m immunocompromised and take medication for high blood pressure, irregular heartbeat and cholesterol. I tested positive for COVID-19 and the flu while traveling to California. Probably the plane ...

The AACE has updated its guidance on obesity and adiposity-based chronic disease to reflect a focus on improving overall ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

Millions of people are now using weight-loss drugs, but it seems there are side-effects that come with the slimmer waistlines ...

He cited one study, which found an average a return to baseline weight in around 1.5 years after taking the medications.

After nonfatal myocardial infarction or stroke, initiation of a GLP-1 receptor agonist was linked to reduced risk for all-cause and CV-related mortality in patients with diabetes, researchers reported ...

A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...

GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.